Our Mission:
Helping People Live Longer, Healthier Lives

At HeartForce, we envision a world where coronary artery disease can be revealed early, accurately, and without unnecessary cost or complexity.

Our founding principles—accessibility, scientific integrity, and meaningful innovation—guide everything we do. We don’t believe CAD assessments should rely on symptoms alone or require complex, costly procedures. With our breakthrough technology, we’re transforming how and when CAD is uncovered.

Healthcare professional holding the CardioClin sensor

A smarter future for heart health

We created CardioClin™ to close the critical gap in CAD assessments:
60 second timer

Fast cardiac signal recording in just 60 seconds, non-invasive, and radiation-free

evidence based

Evidence-based and clinically proven

Intended for both symptomatic and high risk patients illustration

Intended for individuals with CAD-associated risk factors

Scalable across primary care, pharmacies, ambulances, occupational & institutional medicine settings, hospital’s emergency centers and cardiology departments

Scalable across primary care, pharmacies, occupational & institutional medicine settings, and cardiology departments

This is beyond innovation, it’s a transformation. Our EMCR Score™ outperforms traditional screening tests by enhancing accuracy, minimizing unnecessary testing, and assisting healthcare providers in prioritizing resources where they’re most required.

And we're just getting started

HeartForce is developing a full pipeline of user-friendly screening products for a wide range of cardiovascular diseases. Every new product that we create is intended to:

Capture disease before it strikes

Decrease global healthcare costs

Reduce cardiovascular mortality

Enhance quality of life at scale

We believe that longer, healthier lives should be accessible to everyone, and we are committed to making that vision a reality.

Investor Relations

Contact us if you would like to know more about our business plan, revenue model and investment thesis, future product pipeline of other strategic updates.

You are leaving the US website

You are leaving the US version of the HeartForce website and entering our global website.

Product availability, regulatory status, risk categorisation, and performance claims may differ between regions and may not apply to the United States.

CardioClin™ is not cleared or approved by the U.S. Food and Drug Administration (FDA).

Please return to the US website for information applicable to the United States.